WHEREAS, the Lender has agreed to extend certain financial accommodations to the Company in connection with the financing of the working capital needs of the Company and Lender is willing to extend such financial accommodations to the Company pursuant...Pledge Agreement • August 6th, 2001 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.2 DISTRIBUTION AGREEMENTDistribution Agreement • May 14th, 2003 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances)
Exhibit 10.1 FIRST AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT THIS FIRST AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT, dated as of June 20, 2001 (the "Amendment"), by and between SENETEK, plc, a corporation organized under the laws of England...Securities Purchase Agreement • August 6th, 2001 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
1 EXHIBIT 10.13 CONFORMED SETTLEMENT AGREEMENT THIS SETTLEMENT AGREEMENT is entered into as of this 13th day of April 1999 by and among SENETEK PLC a company organized under the laws of England ("Senetek"), SILVER CREEK INVESTMENTS, LTD., a British...Settlement Agreement • August 23rd, 1999 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • California
AMENDED AND RESTATED WARRANT to Purchase [_________] Ordinary Shares of SENETEK PLCSenetek PLC /Eng/ • August 6th, 2001 • Biological products, (no disgnostic substances) • New York
WITNESSETH:Employment Agreement • August 23rd, 1999 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • California
DR. GERLOF HOMAN (2)Agreement • December 9th, 1997 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • England and Wales
SENETEK PLC AMENDED AND RESTATED SENIOR SECURED NOTE DUE APRIL 14, 2004Senetek PLC /Eng/ • August 6th, 2001 • Biological products, (no disgnostic substances) • New York
WITNESSETH:Registration Rights Agreement • August 6th, 2001 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
2 3 exercising any right, power or remedy conferred by this Agreement, or in the enforcement thereof ("Specified Fees and Expenses"), shall become a part of the Secured Obligations and shall be paid to the Secured Party by the Pledgor immediately upon...Pledge Agreement • August 23rd, 1999 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
1 EXHIBIT 10.6 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT, dated as of April 14, 1999, among Senetek P.L.C., a corporation organized under the laws of England (the "Company"), and SILVER CREEK INVESTMENTS, LTD., a British Virgin...Registration Rights Agreement • August 23rd, 1999 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
WHEREAS, the Lender, has agreed to extend certain financial accommodations to the Company in connection with the financing of the working capital needs of the Company, and Lender is willing to extend such financial accommodations to the Company...Guaranty Agreement • August 6th, 2001 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.54 FIRST AMENDMENT TO LICENSE AGREEMENT *** Confidential treatment has been requested as to certain portions of this agreement. Such omitted confidential information has been filed separately with the Securities and Exchange Commission...License Agreement • April 1st, 2002 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances)
SENETEK PLCSecurities Purchase Agreement • April 15th, 1999 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
EXECUTION VERSION REVOLVING CREDIT AGREEMENTRevolving Credit Agreement • August 6th, 2001 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
BACKGROUNDLicense Agreement • April 1st, 2002 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
SENETEK PLC (1) PAUL ANTHONY LOGAN (2) SUPPLEMENTAL AGREEMENTSupplemental Agreement • December 9th, 1997 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances)
Exhibit 10.7 FIRST AMENDMENT TO THE SECURITY AGREEMENTSecurity Agreement • August 6th, 2001 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
WARRANTSenetek PLC /Eng/ • April 1st, 2002 • Biological products, (no disgnostic substances) • New York
BETWEENSenetek PLC /Eng/ • April 9th, 1998 • Biological products, (no disgnostic substances) • New York
BETWEENS Agreement • April 15th, 1999 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
Exhibit 10.53 AMENDMENT TO AGREEMENT *** Confidential treatment has been requested as to certain portions of this agreement. Such omitted confidential information has been filed separately with the Securities and Exchange Commission pursuant to Rule...To Agreement • April 1st, 2002 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances)
EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT made this 1st day of September, 1996 ("Agreement"), by and between SENETEK, PLC, having a place of business at 62A Weldon Parkway, Maryland Heights, Missouri 63048 (hereinafter referred to as "EMPLOYER") and...Employment Agreement • December 9th, 1997 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • Missouri
RECITALSLicense and Supply Agreement • May 14th, 2003 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • California
30 2 EXECUTIVE OFFICER'S AGREEMENTSenetek PLC /Eng/ • April 9th, 1998 • Biological products, (no disgnostic substances) • New York
Exhibit 10.55 DOUGLAS PHARMACEUTICALS LIMITED DEVELOPMENT AND DISTRIBUTION AGREEMENT Distribution of Senetek's Product by Douglas PARTIES DOUGLAS PHARMACEUTICALS LIMITED ("DOUGLAS") SENETEK PLC ("SENETEK") Senetek and Douglas have agreed that together...Senetek PLC /Eng/ • March 28th, 2003 • Biological products, (no disgnostic substances) • England
a) To exercise this Warrant in whole or in part, the Holder shall deliver to the Company at its principal office located at 620 Airpark Road, Napa, California 94558, (A) a written notice, in substantially the form of the Exercise Notice attached...Senetek PLC /Eng/ • August 6th, 2001 • Biological products, (no disgnostic substances) • New York
THIS FIRST AMENDMENT TO THE PATENT AND TRADEMARK SECURITY AGREEMENT, dated as of June 20, 2001 (this "Amendment"), by and between SENETEK, plc, a --------- corporation organized under the laws of England (the "Company") and each of the -------...Patent and Trademark Security Agreement • August 6th, 2001 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
AMENDED WARRANT to Purchase [___________] Ordinary Shares of SENETEK PLCSenetek PLC /Eng/ • January 23rd, 2001 • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.48 DISTRIBUTION AGREEMENT ***Confidential treatment has been requested as to certain portions of this agreement. Such omitted confidential information has been filed separately with the Securities and Exchange Commission pursuant to Rule...Distribution Agreement • April 1st, 2002 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • California
BETWEENSenetek PLC /Eng/ • April 15th, 1999 • Biological products, (no disgnostic substances) • Missouri
SENETEK PLC AND THE BANK OF NEW YORK As Depositary AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS Amended and Restated Deposit Agreement Dated as of November 6, 1992 As Further Amended and Restated as of October 3, 2005Deposit Agreement • April 20th, 2006 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
Amended and Restated Deposit Agreement, dated as of November 6, 1992, to that certain Deposit Agreement dated as of April 15, 1985, as further amended and restated as of October 3, 2005 among SENETEK PLC, incorporated under the laws of England (herein called the Issuer), THE BANK OF NEW YORK, a New York banking corporation (herein called the Depositary), and all Owners from time to time of American Depositary Receipts issued hereunder.
WARRANT to Purchase 2,700,000 Ordinary Shares of SENETEK PLC Issued: March 30, 2006 Expires: March 4, 2011Senetek PLC /Eng/ • April 20th, 2006 • Biological products, (no disgnostic substances) • New York
This Warrant certifies that Wallington Investment Holdings, Ltd. or its registered and permitted successors or assigns (“Wallington” or “Holder”), is entitled to, subject to the terms set forth below, purchase from SENETEK PLC, a corporation organized under the laws of England (the “Company”), from time and time up to Two Million Seven Hundred Thousand (2,700,000) duly authorized, validly issued, fully paid and nonassessable Ordinary Shares (as such number may be adjusted pursuant to Section 4(a) and Section 5 herein) which may be exchanged for American Depositary Shares (“ADSSs”) represented by American Depositary Receipts (“ADRSs”) (the Ordinary Shares of the Company, including any shares into which they may be changed, reclassified, or converted, are herein referred to as the “Ordinary Shares”). This Warrant is one of the Series E Warrants (the “Warrants”) issued pursuant to that certain Agreement dated March 30, 2006, by and between the Company, Silver Creek Investments, Ltd., Bomo
2 3 of the maturity of any of the Company's Liabilities, or by the release or other disposal of any security for any of the Company's Liabilities, or by the dissolution of the Company or the combination or consolidation of the Company into or with...Guaranty Agreement • August 23rd, 1999 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances) • New York
AGREEMENT ON COOPERATIVE RESEARCH AND DEVELOPMENT Institute of Bioorganic Chemistry, Polish Academy of Sciences (hereinafter referred to as “RESEARCHERS”) and Senetek PLC Napa, California 94558 USA (hereinafter referred to as “SENETEK”)Agreement • April 9th, 2007 • Senetek PLC /Eng/ • Biological products, (no disgnostic substances)
WHEREAS the RESEARCHERS are performing basic research on Furfurylcytosine (the “Compounds”) and are willing to provide to SENETEK samples of the Compounds and their analogs and related information developed by the RESEARCHERS, including any covered by patents and/or patent applications owned by the RESEARCHERS, for testing, possible further development by SENETEK, and ultimately possible licensing to and commercialization by SENETEK; and
